Journal
ADVANCED FUNCTIONAL MATERIALS
Volume 23, Issue 48, Pages 6068-6075Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adfm.201300793
Keywords
apoptotic peptides; cell-penetrating peptides; p53 gene; cocktail therapies; doxorubicin
Categories
Funding
- National Basic Research Program of China [973 Program 2013CB932503]
- NSFC, China [91029743, 81172996]
- Shanghai Pu-jiang Scholar Program [11PJ1411800]
- Chinese Postdoctoral Science Foundation [2012M510097, 2013T60478]
- School of Pharmacy, Fudan University & The Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), MOE PLA, China [SDD2011-02]
Ask authors/readers for more resources
The tetra-peptide AVPI, derived from the Smac/DIABLO N-terminal epitope, is able to trigger caspase activation and apoptotic process. However, its clinical value is greatly hampered by the nature of membrane-impermeability. Herein, the cell-penetrating chimeric apoptotic peptide of AVPIR(8) is synthesized, of which the apoptosis-induced AVPI is strategically blended with the cell-penetrating sequence of octaarginine (R-8). The dual-functionalized AVPIR(8) is not only potent in inducing apoptosis in tumor cells due to the cell penetration ability, but also is able to work as gene carrier for transfering the tumor suppressor p53 DNA into cells, thus constructing a co-delivery drug system (AVPIR(8)/p53). Such system efficiently promotes apoptosis in cancer cells while sparing normal cells, and its antitumor activity is further significantly enhanced in combination with doxorubicin as cocktail therapy. More importantly, the anticancer efficacy of the cocktail is demonstrated to be able to arrest tumor growth in two animal tumor models (melanoma and cervical cancers), respectively. The chemotherapeutic dose in the AVPIR(8)/p53-based cocktail is significantly reduced by 80%, compared to the monotherapy of doxorubicin. The present results show the promise of the co-delivered AVPIR(8)/p53 as adjuvant therapy for boosting the conventional chemotherapeutics, with a unique benefit of enhanced productive treatment outcomes yet greatly reduced adverse toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available